Data, Statistical & Economic Analysis
We provide advanced data, statistical and economic analysis to support health technology assessment, pricing, payer and policy decisions in pharmaceutical, biotech and medtech markets.
Connect With An Access Strategist →Analytical evidence shapes reimbursement and payer decisions
Data and analytical evidence underpin critical decisions at every stage of the market access and reimbursement pathway.
Whether quantifying comparative effectiveness, estimating economic value or forecasting budget impact, these analyses directly influence how PBAC, MSAC, payers and policymakers judge value and affordability.
- Comparative effectiveness assessment
- Economic value and affordability analysis
- Budget impact and expenditure forecasting
- HTA-ready evidence interpretation
Transforming complex data into decision-relevant evidence
Pulse Economics partners with sponsors, research organisations and health agencies to bridge the gap between technical modelling and strategic interpretation.
We ensure analysis answers key questions, supports value narratives and anticipates scrutiny from HTA bodies and payers.
Our work combines deep analytical expertise with strong health economics grounding, enabling clients to navigate complex evidence landscapes with confidence.
Analytical and modelling support in practice
Economic, Financial & Outcomes Modelling
Cost-effectiveness, cost-utility analysis, budget impact modelling and financial forecasting.
Comparative Effectiveness & Evidence Synthesis
Systematic evidence synthesis, network meta-analysis and indirect treatment comparisons.
Survival & Real-World Data Modelling
Parametric survival analysis, extrapolation strategies and RWE modelling aligned to HTA expectations.
Statistical & Predictive Analysis
Advanced statistical modelling, uncertainty analysis and predictive frameworks supporting strategy.
Scenario & Sensitivity Analysis
Threshold testing, scenario exploration and probabilistic analysis supporting payer decisions.
HTA-Ready Evidence Interpretation
Transparent analytical interpretation aligned to reimbursement and policy scrutiny.
Transparent, defensible and decision-ready analysis
Evaluator-Informed Interpretation
We understand how analytical outputs are reviewed and stress-tested in PBAC, MSAC and HTA environments.
Strategic Integration
Analytical findings are connected to pricing, reimbursement and submission strategy.
Transparency & Defensibility
Clear assumptions, rationale and decision logic supporting committee confidence and trust.
Turning analytical complexity into actionable insight
Decision-makers focus on uncertainty — whether around long-term outcomes, comparative value or real-world performance.
Scenario analysis and sensitivity testing
Probabilistic frameworks for uncertainty assessment
Clear visualisation and narrative interpretation
Decision-focused interpretation supporting risk mitigation and value claims
Supporting evidence and funding decisions across the lifecycle
Pre-submission Planning & Evidence Gap Analysis
HTA Submissions Across PBS, MBS & Prescribed List
Pricing Strategy & Payer Negotiation
Policy Evaluation & Public Funding Proposals
Post-decision Monitoring & Real-world Evidence
Analytical expertise aligned to real decision environments
Evaluator-level analytical insight
Deep understanding of how PBAC, MSAC and payer bodies interpret evidence.
Integrated economic and strategic thinking
Connecting statistical analysis with reimbursement, pricing and HTA strategy.
Practical market experience
Experience across pharmaceutical, biotech and medtech decision environments.
Decision-ready analytical communication
Translating complex analysis into actionable and defensible insights.
Build evidence and analysis that support real reimbursement decisions
Align analytical rigour with HTA expectations, payer scrutiny and strategic funding objectives.
Connect With An Access Strategist →